HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
15.25
+0.03 (0.20%)
Jan 29, 2026, 3:05 PM EST - Market open
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $138.84M in the half year ending June 30, 2025, a decrease of -9.16%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.33
Revenue / Employee
$338,313
Employees
1,780
Market Cap
2.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | 41.36M | 89.97% |
| Dec 31, 2013 | 45.97M | 23.60M | 105.53% |
| Dec 31, 2012 | 22.37M | -142.66M | -86.45% |
| Dec 31, 2011 | 165.03M | 127.17M | 335.88% |
| Dec 31, 2005 | 37.86M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.03B |
| Perrigo Company | 4.28B |
| Prestige Consumer Healthcare | 1.11B |
| ANI Pharmaceuticals | 826.88M |
| Supernus Pharmaceuticals | 681.54M |
| BioCryst Pharmaceuticals | 599.82M |
| Kiniksa Pharmaceuticals International, | 597.97M |
| Alvotech | 573.35M |
HCM News
- 15 days ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 22 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 22 days ago - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 24 days ago - HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 4 weeks ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification - GlobeNewsWire
- 4 weeks ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma - GlobeNewsWire
- 6 weeks ago - HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - GlobeNewsWire
- 2 months ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - GlobeNewsWire